Corcept Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Corcept Therapeutics (CORT).

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Sell

Consensus RatingBuy# Analysts6Avg. Consensus PT$127Upside to Avg. PT+6.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 18, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$165
Jul 30, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$88→$165
Jul 30, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$150→$161
Jul 30, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$95→$165
Jul 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$135→$150
Jul 27, 2026	Wolfe Research	Kalpit Patel	Downgrade	Peer Perform→Underperform	$50
May 28, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$110→$135
May 28, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$75→$95
May 13, 2026	UBS	Ashwani Verma	Upgrade	Neutral→Buy	$44→$72
May 4, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$60→$75
May 1, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$73→$88
Mar 26, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$100→$110
Mar 26, 2026	Wolfe Research	Kalpit Patel	Upgrade	Underperform→Peer Perform	—
Mar 25, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$67→$60
Feb 25, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$67→$60
Feb 20, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$105→$67
Jan 23, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$99→$100
Jan 23, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$90→$105
Jan 2, 2026	Canaccord Genuity	Edward Nash	PT Cut	Buy	$140→$99
Jan 2, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$145→$90

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $165 price target.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $150 to $161.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $95 to $165.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $135 to $150.

Benzinga Newsdesk

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.

Avi Kapoor

Corcept Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Corcept Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

PRO
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

PRO
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

People Also Watch

People Also Watch

Corcept Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Corcept Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

PROPiper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

PROCanaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

PROHC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

PROCanaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

PRO
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

PRO
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150